Drugs / Larazotide
Larazotide
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01730469 | Aug 2011 → Apr 2012 | Fabry disease | Amicus Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00386490 | Jan → Feb 2006 | — | 9 Meters Biopharma, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00386165 | Nov 2005 → Jan 2006 | celiac disease | 9 Meters Biopharma, Inc. | Completed | No outcome recorded |
| Phase 27 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT05747534 | May 2023 → Jun 2026 overdue | long COVID-19 | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05022303 | Oct 2021 → May 2024 | COVID-19, COVID-19–associated multisystem inflammatory syndrome in children | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT01396213 | Nov 2011 → Aug 2013 | celiac disease | 9 Meters Biopharma, Inc. | Completed | Met primary |
| Phase 2 | NCT00889473 | Apr → Nov 2009 | celiac disease | 9 Meters Biopharma, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00620451 | Feb 2008 → Jul 2009 | celiac disease | 9 Meters Biopharma, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00492960 | Aug 2007 → Oct 2008 | celiac disease | 9 Meters Biopharma, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00362856 | Sep 2006 → Mar 2007 | celiac disease | 9 Meters Biopharma, Inc. | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03569007 Comparator | May 2019 → Jul 2022 | celiac disease | 9 Meters Biopharma, Inc. | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Larazotide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03569007 ↗ |
| Known as | AT-1001 (LARAZOTIDE ACETATE) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105646 ↗ |
| Known as | AT-2347 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105646 ↗ |
| Known as | AT1001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01730469 ↗ |
| Known as | Larazotida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105646 ↗ |
| Known as | Larazotide acetate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00889473 ↗ |
| Action | Inhibit | “octapeptide inhibitor of the zonulin receptor” NCT05747534 ↗ |
| Modality | Peptide | “Larazotide acetate is a tight-junction regulator peptide” PMID 22825365 ↗ Jul 2012 |
| Route | Oral | “administered orally in capsules” NCT00362856 ↗ |